◐ Shell
reader mode source ↗
Skip to main page content
Full text links Cite
Display options

Abstract

Psychostimulant, cardiovascular, and temperature actions of stimulants involve adrenergic (norepinephrine), dopaminergic (dopamine), and serotonergic (serotonin) pathways. Stimulants such as amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), or mephedrone can act on the neuronal membrane monoamine transporters NET, DAT, and SERT and/or the vesicular monoamine transporter 2 to inhibit reuptake of neurotransmitter or cause release by reverse transport. Stimulants may have additional effects involving pre- and postsynaptic/junctional receptors for norepinephrine, dopamine, and serotonin and other receptors. As a result, stimulants may have a wide range of possible actions. Agents with cocaine or MDMA-like actions can induce serious and potentially fatal adverse events via thermodysregulatory, cardiovascular, or other mechanisms. MDMA-like stimulants may cause hyperthermia that can be life threathening. Recreational users of stimulants should be aware of the dangers of hyperthermia in a rave/club environment.

PubMed Disclaimer

References

    1. Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Brit J Pharmacol. 2008;154:606-622.
    1. Drezner JA. Sudden cardiac death in young athletes. Causes, athlete's heart, and screening guidelines. Postgrad Med. 2000;108:37-44:47-50.
    1. Regan L, Mitchelson M, MacDonald C. Mephedrone toxicity in a Scottish emergency department. Eur Med J. 2011;28:1055-1058.
    1. Substance Abuse and Mental Health Service Administration. National survey of drug use and health. 2018-2019. www.samhsa.gov. Accessed Feb 2021.
    1. Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? Effects of MDMA on prosocial feelings and identification of emotional states in others. Biol Psychiatry. 2010;68(12):1134-1140.
Show all 187 references

Publication types

MeSH terms

LinkOut - more resources